AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10911512 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg and Ibuprofen 600 mg concomitantly
Number of subjects: 17
Study 10911512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg and Zaleplon 10 mg concomitantly
Number of subjects: 17
Study 8612031 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min cycle ergometry at approximately 100 W (mean 98.8 W; range 34‐151 W)
Number of subjects: 11
Study 8612031 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min cycle ergometry
Number of subjects: 11
Study 8612031 — intervention group
Group type: COMPARATOR
Intervention: Control day without exercise
Number of subjects: 11
Study 1598509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin treatment at 6-month intervals for two years
Number of subjects: 0
Study 1598509 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment at 6-month intervals for two years
Number of subjects: 0
Study 6427820 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (IMI) administered orally
Number of subjects: 4
Study 6427820 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (IMI) administered intramuscularly
Number of subjects: 4
Study 6427820 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (IMI) and its metabolites
Number of subjects: 4
Study 29861827 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 km time trial run at 18:00 hs
Number of subjects: 13
Study 29861827 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 km time trial run at 09:00 hs
Number of subjects: 13
Study 29861827 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of IL-6, HSP70, WBC, neutrophil, lymphocyte, and CC16 concentrations
Number of subjects: 13
Study 27267588 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 430
Study 27267588 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 430
Study 27267588 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Symptoms (DS)
Number of subjects: 430
Study 27267588 — intervention group
Group type: COMPARATOR
Intervention: Control group (no depression symptoms)
Number of subjects: 430
Study 25038355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1785
Study 25038355 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF
Number of subjects: 1785
Study 25038355 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC+TDF
Number of subjects: 1785
Study 25038355 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP (TDF or FTC+TDF)
Number of subjects: 1785
Study 22345429 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide acetate
Number of subjects: 30
Study 22345429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20339879 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol infusion (0.125 mg/kg/min for 1 min, then 0.01‐0.04 mg/kg/min until 6 h after anesthesia)
Number of subjects: 30
Study 20339879 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol infusion
Number of subjects: 30
Study 20339879 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 30
Study 18525385 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention (INT) involving a diary of physical activities and quarterly group meetings
Number of subjects: 228
Study 18525385 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (usual care)
Number of subjects: 228
Study 18525385 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention (INT)
Number of subjects: 228
Study 15935231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 147
Study 15935231 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 147
Study 12771001 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-I/phosphatidylcholine (apoA-I/PC) disks infusion
Number of subjects: 18
Study 12771001 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements in ABCA1 heterozygotes
Number of subjects: 18
Study 10801996 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg twice daily)
Number of subjects: 116
Study 10801996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 8857615 — intervention group
Group type: EXPERIMENTAL
Intervention: 5F catheter (group BPH 1)
Number of subjects: 64
Study 8857615 — intervention group
Group type: EXPERIMENTAL
Intervention: 10F filling catheter (group BPH 2)
Number of subjects: 64
Study 8857615 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonobstructed)
Number of subjects: 64
Study 1514342 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (12.5 micrograms/kg)
Number of subjects: 90
Study 1514342 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (20 micrograms/kg)
Number of subjects: 90
Study 1514342 — intervention group
Group type: COMPARATOR
Intervention: Regional anesthesia (with any premedication)
Number of subjects: 90
Study 1514342 — intervention group
Group type: COMPARATOR
Intervention: Premedication (any)
Number of subjects: 90
Study 6329395 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole administered 4 to 5 hours before each fraction of radiotherapy (total of 11 to 13 g/m2)
Number of subjects: 267
Study 6329395 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 4 to 5 hours before each fraction of radiotherapy
Number of subjects: 267
Study 6329395 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole
Number of subjects: 267
Study 30230376 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment by orthodontists
Number of subjects: 60
Study 30230376 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment by radiologists
Number of subjects: 60
Study 28324822 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Surgery (MIS)
Number of subjects: 21
Study 28324822 — intervention group
Group type: COMPARATOR
Intervention: Open Reduction Internal Fixation (ORIF)
Number of subjects: 21
Study 25592045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 58
Study 25592045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 23255688 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg/kg/day of elemental zinc
Number of subjects: 614
Study 23255688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study 21310311 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day clopidogrel
Number of subjects: 50
Study 21310311 — intervention group
Group type: COMPARATOR
Intervention: 75 mg/day clopidogrel
Number of subjects: 50
Study 19772583 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 638
Study 19772583 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 638
Study 17032099 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy/cognitive‐behavioral therapy (MET/CBT) plus contingency management (CM)
Number of subjects: 136
Study 17032099 — intervention group
Group type: COMPARATOR
Intervention: Motivational enhancement therapy/cognitive‐behavioral therapy (MET/CBT) without CM
Number of subjects: 136
Study 17032099 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual drug counseling (DC) plus CM
Number of subjects: 136
Study 17032099 — intervention group
Group type: COMPARATOR
Intervention: DC without CM
Number of subjects: 136
Study 12775205 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment (20 min)
Number of subjects: 10
Study 12775205 — intervention group
Group type: COMPARATOR
Intervention: Undisturbed side lying (20 min)
Number of subjects: 10
Study 12775205 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Number of subjects: 10
Study 12775205 — intervention group
Group type: COMPARATOR
Intervention: Undisturbed side lying
Number of subjects: 10
Study 11816733 — intervention group
Group type: EXPERIMENTAL
Intervention: Activelle (1 mg 17 beta‐estradiol combined with 0.5 mg norethisterone acetate)
Number of subjects: 100
Study 11816733 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 women)
Number of subjects: 100
Study 9196674 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular viewing conditions
Number of subjects: 16
Study 9196674 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular but non-stereoscopic viewing conditions
Number of subjects: 16
Study 9196674 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal binocular viewing conditions
Number of subjects: 16
Study 9196674 — intervention group
Group type: COMPARATOR
Intervention: Frisby stereotest (control)
Number of subjects: 16
Study 7931881 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion supplemented with gamma-linolenic acid and long-chain triglycerides (LCT)
Number of subjects: 59
Study 7931881 — intervention group
Group type: COMPARATOR
Intervention: LCT emulsion
Number of subjects: 59
Study 7931881 — intervention group
Group type: COMPARATOR
Intervention: 50% (wt/wt) mixture of medium-chain triglycerides and LCT emulsion
Number of subjects: 59
Study 2887430 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous streptokinase (1.5 MU over one hour)
Number of subjects: 619
Study 2887430 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aspirin (325 mg on alternate days for 28 days)
Number of subjects: 619
Study 2887430 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin (1000 IU h‐1 for 48 hours)
Number of subjects: 619
Study 29683078 — intervention group
Group type: EXPERIMENTAL
Intervention: Grand Theft Auto (experimental group)
Number of subjects: 0
Study 29683078 — intervention group
Group type: COMPARATOR
Intervention: Madden NFL 12 (control group)
Number of subjects: 0
Study 28708221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) intravitreal implant
Number of subjects: 18
Study 26396166 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centred, activities of daily living intervention
Number of subjects: 183
Study 26396166 — intervention group
Group type: COMPARATOR
Intervention: Usual activities of daily living
Number of subjects: 183
Study 25919281 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10)
Number of subjects: 102
Study 25919281 — intervention group
Group type: COMPARATOR
Intervention: Control group (common drugs only)
Number of subjects: 102
Study 23463093 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (30 patients)
Number of subjects: 113
Study 23463093 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant radiotherapy (83 patients)
Number of subjects: 113
Study 23463093 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (10 positive patients)
Number of subjects: 113
Study 23463093 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recurrence (all patients)
Number of subjects: 113
Study 23463093 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy area recurrence (all patients)
Number of subjects: 113
Study 23463093 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 113
Study 23463093 — intervention group
Group type: EXPERIMENTAL
Intervention: T status
Number of subjects: 113
Study 22123359 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan
Number of subjects: 8
Study 22123359 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 8
Study 22123359 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Conivaptan and Furosemide
Number of subjects: 8
Study 19447264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment at L5 using manually assisted mechanical force (Activator)
Number of subjects: 51
Study 19447264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment at L5 using traditional diversified technique spinal manipulation
Number of subjects: 51
Study 19447264 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment in pain-free group
Number of subjects: 51
Study 19447264 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 19447264 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment pain-free group
Number of subjects: 51
Study 19447264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham pain group
Number of subjects: 51
Study 19447264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham pain-free group
Number of subjects: 51
Study 19447264 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment pain group
Number of subjects: 51
Study 16931460 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training
Number of subjects: 14
Study 16931460 — intervention group
Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 14
Study 12921476 — intervention group
Group type: EXPERIMENTAL
Intervention: SLI381 10 mg
Number of subjects: 51
Study 12921476 — intervention group
Group type: EXPERIMENTAL
Intervention: SLI381 20 mg
Number of subjects: 51
Study 12921476 — intervention group
Group type: EXPERIMENTAL
Intervention: SLI381 30 mg
Number of subjects: 51
Study 12921476 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall 10 mg
Number of subjects: 51
Study 11121915 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-229 1.25 mg
Number of subjects: 589
Study 11121915 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-229 2.5 mg
Number of subjects: 589
Study 11121915 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-229 5 mg
Number of subjects: 589
Study 11121915 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-229 10 mg
Number of subjects: 589
Study 11121915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 589
Study 9174180 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (25 mg/kg) administered alone
Number of subjects: 8
Study 9174180 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (25 mg/kg) administered with cimetidine
Number of subjects: 8
Study 9174180 — intervention group
Group type: COMPARATOR
Intervention: Comparison with other regimens
Number of subjects: 8
Study 1606596 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate 3.75 mg every 4 weeks (n = 9)
Number of subjects: 40
Study 1606596 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate 7.5 mg every 4 weeks (n = 16)
Number of subjects: 40
Study 1606596 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate 7.5 mg monthly injections (postmenopausal study, n = 15)
Number of subjects: 40
Study 1606596 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate (both doses)
Number of subjects: 40
Study 1606596 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate (postmenopausal study)
Number of subjects: 40
Study 3022036 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus chest irradiation (40 Gy between cycles 1 and 2)
Number of subjects: 50
Study 3022036 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 50
Study 3022036 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus chest irradiation
Number of subjects: 50
Study 31497981 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive interventions (AIs) for promoting weight loss
Number of subjects: 0
Study 31497981 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 29793868 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cmH2O of positive end-expiratory pressure (PEEP) for 1 hour
Number of subjects: 17
Study 29793868 — intervention group
Group type: COMPARATOR
Intervention: 5 cmH2O of positive end-expiratory pressure (PEEP) for 1 hour
Number of subjects: 17
Study 27197280 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption prior to breast cancer diagnosis
Number of subjects: 7835
Study 27197280 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption prior to breast cancer diagnosis among ER(-) patients
Number of subjects: 7835
Study 27197280 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption prior to breast cancer diagnosis among ER(+) patients
Number of subjects: 7835
Study 24036024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous cardiosphere-derived cells (CDCs) (12.5 to 25 × 10(6))
Number of subjects: 17
Study 24036024 — intervention group
Group type: COMPARATOR
Intervention: Routine-care control
Number of subjects: 17
Study 22854401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose with whole blackcurrants (150 g served as purées) and 35 g added sucrose
Number of subjects: 20
Study 22854401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose with lingonberries (150 g served as purées) and 35 g added sucrose
Number of subjects: 20
Study 22854401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose with blackcurrant nectar (300 mL) and 35 g added sucrose
Number of subjects: 20
Study 22854401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose with lingonberry nectar (300 mL) and 35 g added sucrose
Number of subjects: 20
Study 22854401 — intervention group
Group type: COMPARATOR
Intervention: Sucrose alone (35 g in 300 mL water)
Number of subjects: 20
Study 20456744 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6*1/*1
Number of subjects: 40
Study 20456744 — intervention group
Group type: COMPARATOR
Intervention: CYP2D6*2/*2
Number of subjects: 40
Study 20456744 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6*2/*10
Number of subjects: 40
Study 20456744 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6*10/*10
Number of subjects: 40
Study 18563541 — intervention group
Group type: EXPERIMENTAL
Intervention: Job placement and support program (PS group)
Number of subjects: 66
Study 18563541 — intervention group
Group type: COMPARATOR
Intervention: Self-placement group (SP group)
Number of subjects: 66
Study 17145527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT) with concurrent chemotherapy (CT)
Number of subjects: 112
Study 17145527 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy using delayed accelerated concomitant boost radiotherapy (CBRT) with concurrent chemotherapy (CT)
Number of subjects: 112
Study 17145527 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT with CT
Number of subjects: 112
Study 17145527 — intervention group
Group type: COMPARATOR
Intervention: CBRT with CT
Number of subjects: 112
Study 17145527 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 112
Study 17145527 — intervention group
Group type: COMPARATOR
Intervention: CBRT
Number of subjects: 112
Study 14505262 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist therapy with leuprolide acetate depot (3.75 mg per month) and tibolone (2.5 mg per day) for 3-6 months
Number of subjects: 0
Study 14505262 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist therapy with leuprolide acetate depot (3.75 mg per month) with add-back therapy of norethindrone acetate (5 mg per day) from the first day of treatment
Number of subjects: 0
Study 11225744 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral continuous oestradiol (2.0 mg) + norethisterone acetate (1.0 mg) per day
Number of subjects: 46
Study 11225744 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal oestrogen‐only (50 mg/day)
Number of subjects: 46
Study 11225744 — intervention group
Group type: COMPARATOR
Intervention: Healthy postmenopausal control women
Number of subjects: 46
Study 11225744 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women with metabolic syndrome
Number of subjects: 46
Study 11225744 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women with type 2 diabetes
Number of subjects: 46
Study 9180492 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-system suction catheter (CSSC)
Number of subjects: 20
Study 9180492 — intervention group
Group type: COMPARATOR
Intervention: Open-system suction catheter (OSSC)
Number of subjects: 20
Study 1588353 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and psychosocial status
Number of subjects: 229
Study 1588353 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and quality of life in married women who received segmental mastectomy
Number of subjects: 229
Study 1588353 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, psychosocial status, and quality of life in married women who received segmental mastectomy
Number of subjects: 229
Study 1588353 — intervention group
Group type: EXPERIMENTAL
Intervention: Household income and age
Number of subjects: 229
Study 3158260 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg)
Number of subjects: 12
Study 3158260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3158260 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 12
Study 3158260 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term hypoxia
Number of subjects: 12
Study 31255574 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCK-derived H5N1 alum-adjuvanted vaccine (0.5 mL, 7.5, 15, or 30 μg of hemagglutinin)
Number of subjects: 36
Study 31255574 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCK-derived H5N1 alum-adjuvanted vaccine (30 μg HA)
Number of subjects: 36
Study 31255574 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCK-derived H5N1 alum-adjuvanted vaccine
Number of subjects: 36
Study 28389097 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV/dPly/PhtD-10 (3+0 schedule)
Number of subjects: 1200
Study 28389097 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV/dPly/PhtD-30 (3+0 schedule)
Number of subjects: 1200
Study 28389097 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV/dPly/PhtD-30 (2+1 schedule)
Number of subjects: 1200
Study 28389097 — intervention group
Group type: COMPARATOR
Intervention: PHiD-CV
Number of subjects: 1200
Study 25702876 — intervention group
Group type: COMPARATOR
Intervention: Short-term androgen deprivation (4 months) with high-dose radiotherapy (76-82 Gy)
Number of subjects: 355
Study 25702876 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation (24 months) with high-dose radiotherapy (76-82 Gy)
Number of subjects: 355
Study 25702876 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation (24 months)
Number of subjects: 355
Study 23800573 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20mg once daily (n=38)
Number of subjects: 48
Study 23800573 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 48